Under the hood, Ten-Minute Tissue is a simple idea: a liquid that gels. The lead device candidate from Conexeu Sciences stays fluid at room temperature and is designed to set into a stable gel in place at body temperature, within about ten minutes. Once set, it acts as a bioresorbable scaffold while the body rebuilds its own tissue.
That material is the reason Conexeu opened a new research and development facility in Vancouver. The Nasdaq-listed company (CNXU) held a ribbon-cutting on June 23, 2026, at adMare BioInnovations’ M4 Innovation Centre, a 30,000-square-foot hub built for life sciences organizations. Conexeu says it is one of the first companies to operate there. The announcement, dated July 1, was issued on behalf of the company.
One platform, several markets
The lab will be the center of Conexeu’s research, product development and commercialization work. That covers its patented CXU extracellular matrix platform, which the company sums up as one formula and one device built to scale across markets. It also covers B.R.E.A.S.T., a 3D-bioprinted breast matrix designed to help the body regenerate natural tissue after a mastectomy.
Conexeu describes itself as a preclinical-stage company. Its case for the platform rests on more than a decade of work and eleven peer-reviewed publications, which the company says show that the body accepts the material, that its own cells move in and multiply, and that the matrix integrates with surrounding tissue. Patents are issued in the U.S., E.U., Japan and Australia, and one is pending in Canada.
The aesthetics argument
The commercial argument runs through GLP-1 weight-loss drugs. Conexeu says they cause facial and body volume loss that existing tools were not designed to treat, and it estimates the resulting aesthetics market at roughly $2 billion by 2030. The company puts its first 510(k) submission in early 2027, subject to FDA review, with the platform also pointed at wound care and periodontal uses.
“Our work here will strengthen our research and development capabilities,” said Dr. Claudia Chavez-Munoz, Conexeu’s co-founder and chief scientific officer, who added that the programs could improve outcomes for patients across tissue regeneration, wound care and breast reconstruction.
The caveats are the company’s own. A new lab is an operational milestone, not a clinical or commercial one, and Conexeu’s lead programs have not been cleared or approved. Its announcement states that the safety and effectiveness of its device candidates have not been established by the FDA. It also names AbbVie, Eli Lilly, Galderma and Establishment Labs as established players in the field, and says none of them is a comparable or a partner.
